Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis.
The Brief Pain Inventory short form (BPI-sf) is a validated, widely used, self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions. A modified version was used daily in randomised control trials of patients with arthritis undergoing treatment with cyclooxygenase-2 specific inhibitors and non-steroidal anti-inflammatory drugs. Results indicate that the modified BPI-sf, much like the original scale, was internally reliable, consistent over time, and had good construct, as well as convergent and predictive validity in assessment of patients suffering from conditions of chronic pain. Each scale and individual pain intensity item refers to changes in osteoarthritis pain associated with medication use. The modified BPI-sf, like the parent scale, is a valid and reliable tool for situations in which pain is assessed daily and minimises the burden placed on patients to record information necessary for scientific investigations.
Mendoza
Tito
T
Pain Research Group, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA. tmendoza@mdanderson.org
Mayne
Tracy
T
Rublee
Dale
D
Cleeland
Charles
C
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002908:Chronic Disease / Q000188:drug therapy / Q000523:psychology; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000150:complications* / Q000523:psychology; D010146:Pain / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*; D010147:Pain Measurement / Q000379:methods* / Q000523:psychology*; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires / Q000592:standards*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors